 Home > Active Ingredient News > Blood System > APL-106 Treatment of Acute Myeloid Leukemia: Phase III Briddle Study will be initiated.

APL-106 Treatment of Acute Myeloid Leukemia: Phase III Briddle Study will be initiated.

 Last Update: 2020-10-12
 Source: Internet
 Author: User

Tags

vyvanse drug test

addyi drug

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Biopharmaceutical company Apollomic announced today that APL-106 (uproleselan) has been approved by china's National Drug Administration (NMPA) Drug Review Center (CDE) to conduct a Phase III briditation study of APL-106 (uproleselan) in combination with chemotherapy to treat recurrence/difficult acute myeloid leukemia (AML).
acute myeloid leukemia (AML) is a type of cancer caused by excessive growth of bone marrow blood cells, characterized by a large number of abnormal cells growing rapidly in the bone marrow and blood, which interferes with hematosis.
may include tiredness, difficulty breathing, susceptible bruising and bleeding, increased risk of infection, etc.
AML is one of the most common leukaemias in adults," said Dr. Yu Guoliang, global chief executive of Apollomics, a company.
we are pleased that CDE recognizes the need to improve outcomes for this patient population.
we want to start clinical trials in China because we are committed to providing new and effective treatment options for AML patients."
, APL-106 (uproleselan) is fast-track certified by the U.S. Food and Drug Administration (FDA) and a breakthrough therapy certification for the treatment of adult patients with relapsed/difficult-to-treat AML.
APL-106 has also been awarded the FDA and the European Union's "orphan drug title."
.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

SULODEXIDE 99% Almost White Powder Dideu-01112 Dideu

CAS No.: 57821-29-1

Pharmacy Grade

$61.76/G EXW

High Quality GMP / FDA Certificated Liraglutide Powder CAS 204656-20-2 Liraglutide

CAS No.: 204656-20-2

Pharmacy Grade

$30.00/G FOB

Heparin sodium 9041-08-1 vials safe delivery

CAS No.: 9041-08-1

Pharmacy Grade

$1/G EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.